🎉 M&A multiples are live!
Check it out!

Hanmi Pharm Valuation Multiples

Discover revenue and EBITDA valuation multiples for Hanmi Pharm and similar public comparables like Pharming, Galapagos, and Armata Pharmaceuticals.

All Biopharmaceuticals Multiples Sign Up
Hanmi Pharm logo Hanmi Pharm logo

Sign up to access all valuation multiples

Hanmi Pharm Overview

About Hanmi Pharm

Hanmi Pharm Co Ltd is a Korea-based company, engaged in manufacturing and marketing of medicines, medical supplies and raw materials for medicines. The company makes strenuous and enthusiastic efforts to develop treatments for diabetes, obesity, cancer, autoimmune and rare disease to keep everyone's health and improve their quality of life. The group distributes its products within Korean market and to overseas markets.

Founded

1973

HQ

South Korea
Employees

n/a

Website

hanmi.co.kr

Financials

LTM Revenue $1.0B

LTM EBITDA $218M

EV

$2.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Hanmi Pharm Financials

Hanmi Pharm has a last 12-month revenue of $1.0B and a last 12-month EBITDA of $218M.

In the most recent fiscal year, Hanmi Pharm achieved revenue of $1.0B and an EBITDA of $200M.

Hanmi Pharm expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Hanmi Pharm valuation multiples based on analyst estimates

Hanmi Pharm P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $1.0B $1.0B XXX XXX XXX
Gross Profit $490M $565M XXX XXX XXX
Gross Margin 48% 55% XXX XXX XXX
EBITDA $219M $200M XXX XXX XXX
EBITDA Margin 22% 20% XXX XXX XXX
Net Profit $56.4M $99.6M XXX XXX XXX
Net Margin 6% 10% XXX XXX XXX
Net Debt $354M $346M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Hanmi Pharm Stock Performance

As of April 22, 2025, Hanmi Pharm's stock price is KRW 240000 (or $164).

Hanmi Pharm has current market cap of KRW 3.04T (or $2.1B), and EV of KRW 3.35T (or $2.3B).

See Hanmi Pharm trading valuation data

Hanmi Pharm Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.3B $2.1B XXX XXX XXX XXX $7.13

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Hanmi Pharm Valuation Multiples

As of April 22, 2025, Hanmi Pharm has market cap of $2.1B and EV of $2.3B.

Hanmi Pharm's trades at 2.2x LTM EV/Revenue multiple, and 10.5x LTM EBITDA.

Analysts estimate Hanmi Pharm's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Hanmi Pharm and 10K+ public comps

Hanmi Pharm Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.3B XXX XXX XXX
EV/Revenue 2.2x XXX XXX XXX
EV/EBITDA 11.4x XXX XXX XXX
P/E 25.1x XXX XXX XXX
P/E/Growth 0.9x XXX XXX XXX
EV/FCF 25.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Hanmi Pharm Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Hanmi Pharm Valuation Multiples

Hanmi Pharm's NTM/LTM revenue growth is 8%

Hanmi Pharm's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Hanmi Pharm's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Hanmi Pharm's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Hanmi Pharm and other 10K+ public comps

Hanmi Pharm Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 0% XXX XXX XXX XXX
EBITDA Margin 20% XXX XXX XXX XXX
EBITDA Growth -9% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 28% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 11% XXX XXX XXX XXX
G&A Expenses to Revenue 4% XXX XXX XXX XXX
R&D Expenses to Revenue 12% XXX XXX XXX XXX
Opex to Revenue 40% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Streaming Platforms
Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Explore Valuation Multiples by Industry
Sign Up

Hanmi Pharm Public Comps

See public comps and valuation multiples for Biopharmaceuticals and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Hanmi Pharm M&A and Investment Activity

Hanmi Pharm acquired  XXX companies to date.

Last acquisition by Hanmi Pharm was  XXXXXXXX, XXXXX XXXXX XXXXXX . Hanmi Pharm acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Hanmi Pharm

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Hanmi Pharm

When was Hanmi Pharm founded? Hanmi Pharm was founded in 1973.
Where is Hanmi Pharm headquartered? Hanmi Pharm is headquartered in South Korea.
Who is the CEO of Hanmi Pharm? Hanmi Pharm's CEO is Mr. Jae-Hyeon Park.
Is Hanmi Pharm publicy listed? Yes, Hanmi Pharm is a public company listed on KRX.
What is the stock symbol of Hanmi Pharm? Hanmi Pharm trades under 128940 ticker.
When did Hanmi Pharm go public? Hanmi Pharm went public in 2010.
Who are competitors of Hanmi Pharm? Similar companies to Hanmi Pharm include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Hanmi Pharm? Hanmi Pharm's current market cap is $2.1B
What is the current revenue of Hanmi Pharm? Hanmi Pharm's last 12-month revenue is $1.0B.
What is the current EBITDA of Hanmi Pharm? Hanmi Pharm's last 12-month EBITDA is $218M.
What is the current EV/Revenue multiple of Hanmi Pharm? Current revenue multiple of Hanmi Pharm is 2.2x.
What is the current EV/EBITDA multiple of Hanmi Pharm? Current EBITDA multiple of Hanmi Pharm is 10.5x.
What is the current revenue growth of Hanmi Pharm? Hanmi Pharm revenue growth between 2023 and 2024 was 0%.
Is Hanmi Pharm profitable? Yes, Hanmi Pharm is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.

Sign Up 🎦 Book a Call